dc.contributor.author | Mugwanya, KK | |
dc.contributor.author | Wyatt, C | |
dc.contributor.author | Celum, C | |
dc.contributor.author | Donnell, D | |
dc.contributor.author | Kiarie, J | |
dc.contributor.author | Ronald, A | |
dc.contributor.author | Baeten, JM | |
dc.date.accessioned | 2017-05-18T09:01:05Z | |
dc.date.available | 2017-05-18T09:01:05Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-80. doi: 10.1097/QAI.0000000000000868. | en_US |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/26914909 | |
dc.identifier.uri | http://pubmedcentralcanada.ca/pmcc/articles/PMC4770857/ | |
dc.identifier.uri | http://hdl.handle.net/11295/100956 | |
dc.description.abstract | BACKGROUND:
Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) use is associated with a small but statistically significant decline in estimated glomerular filtration rate (eGFR). We investigated the reversibility of eGFR decline among HIV-uninfected adults discontinuing PrEP.
METHODS:
Data were from the Partners PrEP Study, a randomized trial of daily oral TDF and emtricitabine (FTC)-TDF PrEP among African HIV-uninfected men and women with baseline creatinine clearance ≥60 mL/min. Serum creatinine was measured quarterly while on-study medication and at month 1 and 2 after discontinuation. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration Equation.
RESULTS:
A total of 3924 individuals had a poststudy drug serum creatinine measurement after the scheduled drug discontinuation (1271 for TDF, 1308 for FTC-TDF, and 1345 for placebo); 65% were men, median age was 35 (range 18-64) years. Median time on study drug was 33 (interquartile range 25-36) months overall, and 36 months (interquartile range 30-36) for TDF and FTC-TDF. Mean eGFR at the last on-treatment visit was 129 mL·min·1.73 m for TDF and 128 mL·min·1.73 m for FTC-TDF versus 131 mL·min·1.73 m for placebo (2-3 mL·min·1.73 m mean decline for PrEP versus placebo, P ≤ 0.01), and this difference reversed by 4 weeks after drug discontinuation (mean eGFR at the first postdrug visit: 130 mL·min 1.73 m in all groups). More than 96% of participants had a confirmed >75% eGFR rebound to baseline level by 8 weeks after drug discontinuation, with similar proportions across treatment groups.
CONCLUSIONS:
In this large, placebo-controlled study of TDF-based PrEP, the small reduction in mean eGFR associated with PrEP reversed within weeks after discontinuation. | en_US |
dc.publisher | University of Nairobi | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.title | Reversibility of glomerular renal function decline in hiv-uninfected men and women discontinuing emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis. | en_US |
dc.type | Article | en_US |